News

U.K. government lifts ban on the use of locally sourced plasma

Lifting the plasma donation ban, the UK becomes less dependent on importing plasma to be used for plasma-derived treatments.

Addressing our Plasma Heroes

Business Insider report addresses potential global plasma shortage.

Plasma Donors at the Border: An International Concern

Mexican nationals with B1/B2 visas welcomed back to help save lives through plasma donation.

Are There More Plasma Shortages in Our Future?

Supply for plasma continues to be tight both in the U.S. and around the world.

International Plasma Awareness Week

IPAW raises awareness for plasma donation and recognizes the contributions of plasma donors.

PI Awareness Month is here

April is primary immunodeficiency (PI) month! Help raise awareness for the PI community and learn how they benefit from plasma.

FDA proposes risk-based rules for plasma and blood donations

On January 27, 2023, the U.S. Food and Drug Administration announced a draft proposal for eligibility rules for blood and blood product donation using “gender-inclusive, individual risk-based questions to reduce the risk of transfusion-transmitted HIV.”

Science-based policies boost plasma donation globally

Science is driving global advancements in policy and allowing more people around the world to donate plasma while ensuring the safety of donors and the plasma collected.

Congressional Plasma Caucus formed to address concerns of constituents

Members of the congressional Plasma Caucus provide a venue to educate legislators on important legislation to provide access to patients who rely on immunoglobulin (Ig) therapy.

Increase plasma supply by harmonizing state regulations

States with regulations exceeding FDA standards create barriers for plasma centers, donors, and patients.

Developments in the plasma collection process increase efficiency

Three new plasma innovations include collecting more plasma per donation, speeding up time to donate, and increasing medicine yield.

Common issues patients face accessing their plasma-derived therapies

Insurance companies create barriers to plasma-derived therapies through copay accumulators, formulary restrictions, prior authorization requirements, and coverage confusion, harming patients with rare diseases.